

Meeting the Challenge


# A Randomized, Phase III Trial of Canakinumab for the Treatment of Patients with Periodic Fever Syndromes<sup>1,2</sup>

## Purpose

To determine if **canakinumab** can induce and maintain a clinically meaningful reduction of disease activity in patients with **Periodic Fever Syndromes** (FMF, TRAPS, HIDS/MKD) compared with placebo



CANAKINUMAB PIVOTAL UMBRELLA STUDY  
IN THREE HEREDITARY PERIODIC FEVERS



FMF, Familial Mediterranean fever; IL, interleukin.

References 1. ClinicalTrials.gov. <https://clinicaltrials.gov/ct2/show/NCT02059291>. 2. Autoinflammation. January 18, 2015. <http://www.autoinflammatie.nl/ENG/folder18/index.php>.